Literature DB >> 18827266

Impact of neurofibromatosis type 1 on school performance.

Lianne C Krab1, Femke K Aarsen, Arja de Goede-Bolder, Coriene E Catsman-Berrevoets, Willem F Arts, Henriette A Moll, Ype Elgersma.   

Abstract

School functioning of 86 Dutch neurofibromatosis type 1 children (7-17 years) using teacher questionnaires was analyzed to determine the impact of neurofibromatosis type 1 on school performance. In all, 75% of the neurofibromatosis type 1 children performed more than 1 standard deviation below grade peers in at least one of the domains of spelling, mathematics, technical reading or comprehensive reading. Furthermore, neurofibromatosis type 1 children had a 4-fold increased risk for attending special education and a 6-fold increased risk for receiving remedial teaching for learning, behavior, speech, or motor problems. Children without apparent learning disabilities still frequently displayed neuropsychological deficits. Only 10% of the children did not show any school-functioning problems. Finally, it was found that the clinical severity of neurofibromatosis type 1 correlated with the cognitive deficits. Taken together, it was shown that neurofibromatosis type 1 has profound impact on school performance. Awareness of these problems may facilitate timely recognition and appropriate support.

Entities:  

Mesh:

Year:  2008        PMID: 18827266     DOI: 10.1177/0883073808316366

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  35 in total

Review 1.  Molecular and cellular mechanisms of learning disabilities: a focus on NF1.

Authors:  C Shilyansky; Y S Lee; A J Silva
Journal:  Annu Rev Neurosci       Date:  2010       Impact factor: 12.449

2.  Disruption of Critical Period Plasticity in a Mouse Model of Neurofibromatosis Type 1.

Authors:  Mariska van Lier; M Hadi Saiepour; Koen Kole; Juliette E Cheyne; Nawal Zabouri; Thomas Blok; Yi Qin; Emma Ruimschotel; J Alexander Heimel; Christian Lohmann; Christiaan N Levelt
Journal:  J Neurosci       Date:  2020-06-11       Impact factor: 6.167

3.  Teaching reading to children with neurofibromatosis type 1: a clinical trial with random assignment to different approaches.

Authors:  Laura A Barquero; Angela M Sefcik; Laurie E Cutting; Sheryl L Rimrodt
Journal:  Dev Med Child Neurol       Date:  2015-04-22       Impact factor: 5.449

4.  Neurofibromin regulates corticostriatal inhibitory networks during working memory performance.

Authors:  Carrie Shilyansky; Katherine H Karlsgodt; Damian M Cummings; Kyriaki Sidiropoulou; Molly Hardt; Alex S James; Dan Ehninger; Carrie E Bearden; Panayiota Poirazi; J David Jentsch; Tyrone D Cannon; Michael S Levine; Alcino J Silva
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

Review 5.  The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research.

Authors:  Maria T Acosta; Carrie E Bearden; F Xavier Castellanos; Xavier F Castellanos; Laurie Cutting; Ype Elgersma; Gerard Gioia; David H Gutmann; Yong-Seok Lee; Eric Legius; Maximillian Muenke; Kathryn North; Luis F Parada; Nancy Ratner; Kim Hunter-Schaedle; Alcino J Silva
Journal:  Am J Med Genet A       Date:  2012-07-20       Impact factor: 2.802

6.  Cognitive profile of children with neurofibromatosis and reading disabilities.

Authors:  Laurie E Cutting; Terry M Levine
Journal:  Child Neuropsychol       Date:  2010       Impact factor: 2.500

7.  Behavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1.

Authors:  Thijs van der Vaart; André B Rietman; Ellen Plasschaert; Eric Legius; Ype Elgersma; Henriëtte A Moll
Journal:  Neurology       Date:  2015-10-30       Impact factor: 9.910

Review 8.  Treatment of neurodevelopmental disorders in adulthood.

Authors:  Eero Castrén; Ype Elgersma; Lamberto Maffei; Randi Hagerman
Journal:  J Neurosci       Date:  2012-10-10       Impact factor: 6.167

9.  Treatment of neurofibromatosis type 1.

Authors:  Caterina Sabatini; Donatella Milani; Francesca Menni; Gianluca Tadini; Susanna Esposito
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

10.  HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.

Authors:  A Omrani; T van der Vaart; E Mientjes; G M van Woerden; M R Hojjati; K W Li; D H Gutmann; C N Levelt; A B Smit; A J Silva; S A Kushner; Y Elgersma
Journal:  Mol Psychiatry       Date:  2015-04-28       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.